A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

Recruiting now · Phase 2

Conditions studied: Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis

In brief

This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks.

Key facts

Study ID

NCT07170800

Run by

WestVac Biopharma Co., Ltd.

People needed

60

Starts

2025-09-19

Expected to finish

2026-09-04

Last updated by the study team

2026-01-30

Who can join

Age: 14 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age: 14 years through 65 years of age, male or female
• Weight: 40kg ≤ weight ≤ 90kg
• Patients with clinically confirmed pulmonary tuberculosis, Drug Susceptibility Testing (DST) results confirmed to be at least rifampicin-resistant, molecular or phenotypic DST results within 3 months before enrollment can be received
• Sputum acid-fast bacilli smear is positive (≥2+ once or 1+ twice at least)
• Patients who are currently taking anti-tuberculosis treatment or using drugs with anti-tuberculosis effects agree to stop all anti-tuberculosis drug treatment and complete a 7-day washout period
• Women of reproductive age must agree to use highly effective contraceptive measures throughout the study and for at least 6 months after discontinuation of the drug. Male participants whose partners are women of reproductive age must agree to use appropriate contraceptive methods throughout the study and for at least 6 months after discontinuation of the drug (see protocol Appendix 1)
• Fully understand the purpose and requirements of this trial, voluntarily sign the written informed consent and agree to abide by the relevant provisions of the informed consent

You may not qualify if…

• Those who cannot take delamanid, bedaquiline, or linezolid for various reasons
• Take delamanid, bedaquiline, or linezolid for more than 1 month (can be enrolled if evidence of no resistance to the above drugs is provided)
• Hematogenously disseminated pulmonary tuberculosis or severe extrapulmonary tuberculosis as determined by the investigator; or patients with pulmonary tuberculosis who are assessed by the investigator to be likely to require surgical treatment within 8 weeks
• History of torsades de pointes or risk factors, including a personal or family history of long QT syndrome (LQTS), persistent hypothyroidism, or bradycardia
• Anyone with any of the following cardiovascular diseases or other conditions within 6 months before enrollment:
• Myocardial infarction;
• Heart surgery or coronary revascularization (coronary artery bypass grafting/percutaneous transluminal coronary angioplasty);
• Unstable angina;
• Congestive heart failure (New York Heart Association functional class III or IV);
• Transient ischemic attack or severe cerebrovascular disease.
• Peripheral neuropathy CTCAE grade 3 or 4; Grade 1 or 2 peripheral neuropathy that the investigator judges may progress/worsen during the study; Patients with optic neuritis
• History of gastrointestinal surgery or resection that may affect the absorption and/or excretion of oral medications
• Patients who are considered by the investigator to be unsuitable for this trial due to unstable or severe cardiovascular, renal, hepatic, blood, tumor, endocrine metabolic, psychiatric or rheumatic diseases
• History of alcohol dependence or drug abuse within 6 months before screening, the investigator believes that it may affect the safety of the participants and affect the trial compliance
• Patients who have used other clinical trial investigational drugs within 3 months before administration
• Concomitant take drugs that cause bone marrow suppression
• Concomitant take serotonin reuptake inhibitors, tricyclic antidepressants, serotonin, serotonin receptor agonists, and other drugs
• Concomitant take drugs that prolong the QT interval, such as quinidine, procainamide, amiodarone, sotalol, etc.
• Chronic systemic corticosteroid therapy, cumulative take for more than 4 weeks within 3 months before enrollment
• Allergic to any investigational drug or related substance as confirmed by the researcher's clinical judgment
• Women who have a positive pregnancy test during screening or are breastfeeding
• Patients with hepatitis B virus (HBV) positive results (HBsAg, HBeAg, and HBcAb); positive hepatitis C virus (HCV) antibodies and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels >3 times the upper limit of normal; positive Human Immunodeficiency Virus (HIV) antibody test; positive syphilis antibody test and active syphilis
• Laboratory tests show any of the following:
• Hemoglobin < 80 g/L;
• platelets < 75 ✕ 109 /L;

Where it is running

• Wuhan Pulmonary Hospital — Wuhan, Hubei, China (enrolling)
• Changsha Central Hospital — Changsha, Hunan, China (enrolling)
• The Second Hospital of Nanjing — Nanjing, Jiangsu, China (enrolling)
• Shandong Public Health Clinical Center — Jinan, Shandong, China (enrolling)
• Public Health Clinical Center of Chengdu — Chengdu, Sichuan, China (enrolling)
• Beijing Chest Hospital, Capital Medical University — Beijing, China (enrolling)
• Huashan Hospital Fudan University — Shanghai, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.